Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ferric maltol (Accrufer) is indicated for the treatment of iron deficiency in adults.
• The information was derived from two systematic reviews/meta-analyses documents.
• In a study involving adults and children with inflammatory bowel disease (IBD), oral ferric maltol showed low-certainty evidence of being superior to placebo in resolving iron deficiency anemia (IDA).
• Compared to intravenous preparations like IV ferric carboxymaltose, which had moderate-certainty evidence suggesting superiority over IV iron sucrose, oral ferric maltol's effectiveness was less favorable but still notable against placebo.
• Safety profiles indicate that while adverse events were inconsistently reported across studies, there is low-certainty evidence showing little difference in adverse events between oral ferric maltol and placebo.
• Population considerations highlight varying efficacy and safety among different age groups and stages of IBD; more research is needed specifically targeting fatigue management within these subpopulations.